Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07681596 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT07681596 · ClinicalTrials.gov record · last posted 2026-08-27

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

StatusRecruiting
PhasePhase 1/2
Started2026-07-27
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to assess the safety, tolerability, preliminary efficacy, cellular kinetics, and other exploratory endpoints of AZD4045 as a monotherapy and in association with daratumumab and aldesleukin for the treatment of adult participants with RRMM.

Protocol amendment history 3 changes detected by DataLookout

2026-08-28
Recruitment opened
2026-08-28
Primary completion pushed: 2029-10-30 → 2031-03-06
2026-08-28
Completion pushed: 2029-10-30 → 2031-03-06
Trial Details
NCT Number NCT07681596
Lead Sponsor AstraZeneca
Conditions Relapsed or Refractory Multiple Myeloma
Enrollment 101 participants
Start Date 2026-07-27
Primary Completion 2031-03-06 (estimated)
Study Completion 2031-03-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-27